WO2008048306A3 - Influenza a virus vaccines and inhibitors - Google Patents

Influenza a virus vaccines and inhibitors Download PDF

Info

Publication number
WO2008048306A3
WO2008048306A3 PCT/US2006/046239 US2006046239W WO2008048306A3 WO 2008048306 A3 WO2008048306 A3 WO 2008048306A3 US 2006046239 W US2006046239 W US 2006046239W WO 2008048306 A3 WO2008048306 A3 WO 2008048306A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza
avian
inhibitors
virus vaccines
flu
Prior art date
Application number
PCT/US2006/046239
Other languages
French (fr)
Other versions
WO2008048306A2 (en
Inventor
Gaetano Montelione
Kalyan Das
Edward Arnold
Lichung Ma
Rong Xiao
Robert M Krug
Karen Y Twu
Rei-Lin Kuo
Original Assignee
Univ Texas
Univ Rutgers
Gaetano Montelione
Kalyan Das
Edward Arnold
Lichung Ma
Rong Xiao
Robert M Krug
Karen Y Twu
Rei-Lin Kuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Univ Rutgers, Gaetano Montelione, Kalyan Das, Edward Arnold, Lichung Ma, Rong Xiao, Robert M Krug, Karen Y Twu, Rei-Lin Kuo filed Critical Univ Texas
Publication of WO2008048306A2 publication Critical patent/WO2008048306A2/en
Publication of WO2008048306A3 publication Critical patent/WO2008048306A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NSl). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.
PCT/US2006/046239 2006-10-16 2006-12-02 Influenza a virus vaccines and inhibitors WO2008048306A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85236106P 2006-10-16 2006-10-16
US60/852,361 2006-10-16

Publications (2)

Publication Number Publication Date
WO2008048306A2 WO2008048306A2 (en) 2008-04-24
WO2008048306A3 true WO2008048306A3 (en) 2008-08-07

Family

ID=39314543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046239 WO2008048306A2 (en) 2006-10-16 2006-12-02 Influenza a virus vaccines and inhibitors

Country Status (1)

Country Link
WO (1) WO2008048306A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601490B2 (en) 2005-12-02 2009-10-13 Board Of Regents, The University Of Texas System Development of influenza A antivirals
US7709190B2 (en) 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2708552A1 (en) 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TWU ET AL.: "The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target", J. VIROL., vol. 80, no. 8, April 2006 (2006-04-01), pages 3957 - 3965 *

Also Published As

Publication number Publication date
WO2008048306A2 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
Fouchier et al. Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene
WO2007019094A3 (en) Modified influenza virus for monitoring and improving vaccine efficiency
WO2007098184A3 (en) Methods and compositions for analyte detection
EA200870542A1 (en) METHODS OF DETECTION OF VIRUSES OF INFLUENZA
WO2010132453A3 (en) Methods and compositions for analyte detection
WO2009053604A3 (en) Influenza virus haemagglutinin-specific monoclonal antibodies
WO2007047778A3 (en) Compositions for use in identification of influenza viruses
WO2006093797A3 (en) Method and kit for detecting porcine reproductive and respiratory syndrome virus
WO2010021681A3 (en) Compositions and methods for treatment of viral diseases
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2006122312A3 (en) Methods of testing using a microfluidic cassette
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
BRPI0606260A2 (en) virus, isolated or recombinant nucleic acid or specific fragment thereof for totv, expression vector, polynucleotide, antigen, antibody, methods for producing an antibody against totv, to identify a viral isolate as a totv virus, to detect the presence of totv in a sample, and to identify and produce a totv-resistant plant, totv-resistant plant, or part of it, diagnostic kit, use of a virus, diagnostic composition, use of a virus, or its genome, or parts of it, and , use of an attenuated form of a virus, or its genome, or parts of it
Sun et al. A serological survey of canine H3N2, pandemic H1N1/09 and human seasonal H3N2 influenza viruses in dogs in China
BRPI0908489A2 (en) use of chemical compounds and method for designing chemical compounds that attenuate or inhibit dengue virus infection
WO2006131936A3 (en) Hepatitis c virus vaccine
WO2007133682A3 (en) 100% sequence identity detection methods for variable genomes
EP2363415A3 (en) H5 subtype-specific binding proteins useful for H5 avian influenza diagnosis and surveillance
WO2005067643A8 (en) Determination of hepatitis c virus genotype
Daum et al. Real‐time RT‐PCR assays for type and subtype detection of influenza A and B viruses
BR112013016495A2 (en) A monoclonal antibody which recognizes human papilloma virus (HPV) L2 protein, and a HPV neutralization antibody value measuring method which uses it
BRPI1003743A2 (en) REAGENTS FOR HCV ANTIGEN-ANTIBODY COMBINATION TESTS
WO2007049276A3 (en) Compositions for- detecting of influenza viruses and kits and methods using same
WO2010128396A3 (en) Generic assays for detection of influenza viruses
WO2008048306A3 (en) Influenza a virus vaccines and inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06847495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847495

Country of ref document: EP

Kind code of ref document: A2